ArticleJournal of experimental & clinical cancer research : CR2018
PHD-finger domain protein 5A functions as a novel oncoprotein in lung adenocarcinoma.
Article in Journal of experimental & clinical cancer research : CR, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 51 citations in OpenAlex.
- Correction: PHD-finger domain protein 5A functions as a novel oncoprotein in lung adenocarcinoma.Journal of experimental & clinical cancer research : CR · 2026Article
- Deciphering Shared Gene Signatures and Immune Infiltration Characteristics Between Gestational Diabetes Mellitus and Preeclampsia by Integrated Bioinformatics Analysis and Machine Learning.Reproductive sciences (Thousand Oaks, Calif.) · 2025Article
- Splicing control by PHF5A is crucial for melanoma cell survival.Cell proliferation · 2025Article
- Comprehensive analysis of PHF5A as a potential prognostic biomarker and therapeutic target across cancers and in hepatocellular carcinoma.BMC cancer · 2024Article
- PHF5A promotes esophageal squamous cell carcinoma progression via stabilizing VEGFA.Biology direct · 2024Article
- FFAR4 activation inhibits lung adenocarcinoma via blocking respiratory chain complex assembly associated mitochondrial metabolism.Cellular & molecular biology letters · 2024Article
- Synthesis and Conformational Analysis of FR901464-Based RNA Splicing Modulators and Their Synergism in Drug-Resistant Cancers.Journal of medicinal chemistry · 2023Article
- PHF5A is a potential diagnostic, prognostic, and immunological biomarker in pan-cancer.Scientific reports · 2023Article
- KMT2A associates with PHF5A-PHF14-HMG20A-RAI1 subcomplex in pancreatic cancer stem cells and epigenetically regulates their characteristics.Nature communications · 2023Article
- PHF5A regulates the expression of the DOCK5 variant to promote HNSCC progression through p38 MAPK activation.Biology direct · 2023Article
- PHF5A as a new OncoTarget and therapeutic prospects.Heliyon · 2023Review
- Research progress and therapeutic prospect of PHF5A acting as a new target for malignant tumors.Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2022Review
- PHF5A promotes colorectal cancerprogression by alternative splicing of TEAD2.Molecular therapy. Nucleic acids · 2021Article
- Overlapping roles of spliceosomal components SF3B1 and PHF5A in rice splicing regulation.Communications biology · 2021Article
- The SF3b complex: splicing and beyond.Cellular and molecular life sciences : CMLS · 2020Review
- PHD finger protein 5A promoted lung adenocarcinoma progression via alternative splicing.Cancer medicine · 2019Article
- Knockdown of PHF5A Inhibits Migration and Invasion of HCC Cells via Downregulating NF-BioMed research international · 2019Article
- MicroRNA-302a/d inhibits the self-renewal capability and cell cycle entry of liver cancer stem cells by targeting the E2F7/AKT axis.Journal of experimental & clinical cancer research : CR · 2018Article
- The Dysregulation of Lysine Acetylation in Esophageal Squamous Cell Carcinoma: Mechanisms, Therapeutic Targets and Clinical Perspectives.Technology in cancer research & treatmentReview
Corrections and comments
- Erratum issued
Authors and funding
11 authors at 1 institution in 1 country.
Funding
Abstract
backgroundPHD-finger domain protein 5A (PHF5A) is a highly conserved small transcriptional regulator also involved in pre-mRNA splicing; however, its biological functions and molecular mechanisms in non-small cell lung cancer (NSCLC) have not yet been investigated. The purpose of this study was to determine the functional relevance and therapeutic potential of PHF5A in lung adenocarcinoma (LAC).
methodsThe expression of PHF5A in LAC tissues and adjacent non-tumor (ANT) tissues was investigated using immunohistochemistry of a tissue microarray, qRT-PCR, western blot and bioinformatics. The function of PHF5A was determined using several in vitro assays and also in vivo assay by lentiviral vector-mediated PHF5A depletion in LAC cell lines.
resultsPHF5A was highly upregulated in LAC tissues compared with the ANT counterparts, and closely associated with tumor progression and poor patient prognosis. These results were further confirmed by findings of the TCGA database. Moreover, functional studies demonstrated that PHF5A knockdown not only resulted in reduced cell proliferation, increased cell apoptosis, and cell cycle arrest, but also suppressed migration and invasion in LAC cells. PHF5A silencing was also found to inhibit LAC tumor growth in nude mice. Microarray and bioinformatics analyses revealed that PHF5A depletion led to dysregulation of multiple tumor signaling pathways; selected factors in key signaling pathways were verified in vitro.
conclusionsThe data suggest for the first time that PHF5A is an oncoprotein that contributes to LAC progression by regulating multiple signaling pathways, and may constitute a prognostic factor and potential new therapeutic target in NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.